FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2522451448> ?p ?o ?g. }

• W2522451448 abstract "Study Objective. To evaluate the efficacy and safety of using the anti–tumor necrosis factor- (anti –TNF- ) drugs adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Design. Systematic review and meta-analysis of 21 randomized, placebocontrolled trials (eight adalimumab, seven infliximab, six etanercept). Patients. Adults with rheumatoid arthritis who received adalimumab (1524 patients), infliximab (1116 patients), etanercept (1029 patients), or placebo (2834 patients) with or without concomitant methotrexate in all groups . Measurements and Main Results. A literature search of several databases from January 1995 –December 2008 was performed. There were no restrictions based on language or date of publication, and low-quality studies (based on Jadad score) were excluded. American College of Rheumatology (ACR) 20% improvement criteria (ACR20), 50% improvement criteria (ACR50), and 70% improvement criteria (ACR70) were used to compare treatment efficacy. Safety was compared based on frequency of serious adverse events, serious infections, malignancy, and death. Withdrawals due to adverse events and lack of efficacy were also evaluated. With short-term treatment (12–30 wks), etanercept demonstrated the highest risk ratios (RRs) for reaching ACR20 and ACR50: 2.94 (95% confidence interval [CI] 2.27–3.81) and 5.28 (95% CI 3.12–8.92), respectively. Adalimumab demonstrated the highest RR for achieving ACR70 (5.36, 95% CI 3.76– 7.64). Over a long-term treatment course (1–3 yrs), adalimumab demonstrated the highest RRs (95% CIs) for these parameters: 1.85 (1.07–3.19), 2.80 (1.16–6.77), and 3.23 (1.37–7.61) for ACR20, ACR50, and ACR70, respectively. No statistically significant differences were noted in the safety of any of the three drugs compared with placebo. Infliximab had the highest RRs for withdrawing from the study due to lack of efficacy (2.05, 95% CI 1.33–3.16) and adverse events (0.41, 95% CI 0.18–0.95). Conclusion. With short-term treatment , etanercept and adalimumab had higher efficacy results; with long-term treatment, adalimumab appeared to be the most effective. Clinicians should be aware that each of the three drugs has different rates of efficacy and different safety considerations that must be taken into account when selecting the best treatment for an individual with rheumatoid arthritis." @default.
• W2522451448 created "2016-09-30" @default.
• W2522451448 creator A5022984004 @default.
• W2522451448 creator A5028447247 @default.
• W2522451448 creator A5045403266 @default.
• W2522451448 creator A5055574658 @default.
• W2522451448 creator A5067107891 @default.
• W2522451448 date "2010-01-01" @default.
• W2522451448 modified "2023-09-27" @default.
• W2522451448 title "Meta-analysisoftheEfficacyandSafetyof Adalimumab,Etanercept,andInfliximabforthe TreatmentofRheumatoidArthritis" @default.
• W2522451448 cites W142190074 @default.
• W2522451448 cites W1588168837 @default.
• W2522451448 cites W1833163659 @default.
• W2522451448 cites W1851301093 @default.
• W2522451448 cites W1886534650 @default.
• W2522451448 cites W1921764250 @default.
• W2522451448 cites W1979364075 @default.
• W2522451448 cites W1985763670 @default.
• W2522451448 cites W1986215651 @default.
• W2522451448 cites W1994065448 @default.
• W2522451448 cites W1995228104 @default.
• W2522451448 cites W1996389186 @default.
• W2522451448 cites W1996437423 @default.
• W2522451448 cites W1997106678 @default.
• W2522451448 cites W1999777294 @default.
• W2522451448 cites W2000962647 @default.
• W2522451448 cites W2005429018 @default.
• W2522451448 cites W2009258522 @default.
• W2522451448 cites W2046549669 @default.
• W2522451448 cites W2046628605 @default.
• W2522451448 cites W2060943696 @default.
• W2522451448 cites W2097341637 @default.
• W2522451448 cites W2098767548 @default.
• W2522451448 cites W2109905595 @default.
• W2522451448 cites W2111153776 @default.
• W2522451448 cites W2112475478 @default.
• W2522451448 cites W2117200377 @default.
• W2522451448 cites W2118704147 @default.
• W2522451448 cites W2133541603 @default.
• W2522451448 cites W2133604058 @default.
• W2522451448 cites W2141436693 @default.
• W2522451448 cites W2149456330 @default.
• W2522451448 cites W2155702314 @default.
• W2522451448 cites W2156712409 @default.
• W2522451448 cites W2156996668 @default.
• W2522451448 cites W2159106700 @default.
• W2522451448 cites W2162254515 @default.
• W2522451448 cites W2166732840 @default.
• W2522451448 cites W2168419457 @default.
• W2522451448 cites W2168841149 @default.
• W2522451448 cites W2169853546 @default.
• W2522451448 cites W2172136472 @default.
• W2522451448 cites W2314052274 @default.
• W2522451448 cites W2319957449 @default.
• W2522451448 cites W2340084730 @default.
• W2522451448 cites W2471210286 @default.
• W2522451448 cites W3021178644 @default.
• W2522451448 cites W73945361 @default.
• W2522451448 cites W2122917908 @default.
• W2522451448 hasPublicationYear "2010" @default.
• W2522451448 type Work @default.
• W2522451448 sameAs 2522451448 @default.
• W2522451448 citedByCount "0" @default.
• W2522451448 crossrefType "journal-article" @default.
• W2522451448 hasAuthorship W2522451448A5022984004 @default.
• W2522451448 hasAuthorship W2522451448A5028447247 @default.
• W2522451448 hasAuthorship W2522451448A5045403266 @default.
• W2522451448 hasAuthorship W2522451448A5055574658 @default.
• W2522451448 hasAuthorship W2522451448A5067107891 @default.
• W2522451448 hasConcept C126322002 @default.
• W2522451448 hasConcept C141071460 @default.
• W2522451448 hasConcept C142724271 @default.
• W2522451448 hasConcept C17991360 @default.
• W2522451448 hasConcept C197934379 @default.
• W2522451448 hasConcept C198451711 @default.
• W2522451448 hasConcept C204787440 @default.
• W2522451448 hasConcept C27081682 @default.
• W2522451448 hasConcept C2777138892 @default.
• W2522451448 hasConcept C2777226972 @default.
• W2522451448 hasConcept C2777575956 @default.
• W2522451448 hasConcept C2780132546 @default.
• W2522451448 hasConcept C44249647 @default.
• W2522451448 hasConcept C71924100 @default.
• W2522451448 hasConceptScore W2522451448C126322002 @default.
• W2522451448 hasConceptScore W2522451448C141071460 @default.
• W2522451448 hasConceptScore W2522451448C142724271 @default.
• W2522451448 hasConceptScore W2522451448C17991360 @default.
• W2522451448 hasConceptScore W2522451448C197934379 @default.
• W2522451448 hasConceptScore W2522451448C198451711 @default.
• W2522451448 hasConceptScore W2522451448C204787440 @default.
• W2522451448 hasConceptScore W2522451448C27081682 @default.
• W2522451448 hasConceptScore W2522451448C2777138892 @default.
• W2522451448 hasConceptScore W2522451448C2777226972 @default.
• W2522451448 hasConceptScore W2522451448C2777575956 @default.
• W2522451448 hasConceptScore W2522451448C2780132546 @default.
• W2522451448 hasConceptScore W2522451448C44249647 @default.
• W2522451448 hasConceptScore W2522451448C71924100 @default.
• W2522451448 hasLocation W25224514481 @default.
• W2522451448 hasOpenAccess W2522451448 @default.
• W2522451448 hasPrimaryLocation W25224514481 @default.

• next